NCT05104684

Brief Summary

evaluate the efficacy of Chest Physical Therapy (CPT) performed during the pre-transplant period on spirometric values as well as Respiratory Muscle Strength (RMS) in patients waiting for Allogeneic Hematopoietic Stem Cell Transplantation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 12, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2021

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

October 9, 2021

Completed
25 days until next milestone

First Posted

Study publicly available on registry

November 3, 2021

Completed
Last Updated

November 3, 2021

Status Verified

October 1, 2021

Enrollment Period

7 months

First QC Date

October 9, 2021

Last Update Submit

October 21, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Spirometry measures1

    The forced expiratory volume in one second (FEV1), FEV1 is the volume of air exhaled in the first second of the FVC maneuver

    Change from Baseline (three weeks before HSCT) , the end of treatment immediately before HSCT(T1) to three weeks after HSCT(T2) for all measured variables.

  • Spirometry measures2

    the forced vital capacity (FVC)To measure FVC, the patient inhales maximally, then exhales as rapidly and as completely as possible.

    Change from Baseline (three weeks before HSCT) , the end of treatment immediately before HSCT(T1) to three weeks after HSCT(T2) for all measured variables.

  • Spirometry measures3

    the relation between FEV1 and FVC

    Change from Baseline (three weeks before HSCT) , the end of treatment immediately before HSCT(T1) to three weeks after HSCT(T2) for all measured variables.

Secondary Outcomes (1)

  • Respiratory muscle strength (RMS)

    A baseline assessment will be done three weeks before HSCT (T0) then at the end of treatment immediately before HSCT(T1) and the last assessment at three weeks after HSCT(T2) for all measured varibles.

Study Arms (2)

group A:Chest Physical Therapy

EXPERIMENTAL

Patients in group A will receive CPT program daily for three weeks before HSCT (hospital stay for allogeneic-HCT). The program consists of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment. The total duration of each CPT session ranged from 45-60 minutes according to patient tolerance. The choice of airway clearance method that will be applied depends on two factors; patient preference and the individual response of the patient to treatment.

Other: chest physical therapyOther: routine medical treatment

Control group (B):Routine medical treatment

ACTIVE COMPARATOR

patients in group B will receive routine medical treatment

Other: routine medical treatment

Interventions

The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment

Also known as: chest p.t
group A:Chest Physical Therapy

medical treatment

Control group (B):Routine medical treatmentgroup A:Chest Physical Therapy

Eligibility Criteria

Age40 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients consecutively admitted to HSCT unit, completed the induction therapy and awaiting for allogeneic HSCT Study. Candidates' ages from 40-55 years old, both males and females will be included, Non-smokers patients, Non-alcoholics patients, patients medically cleared to exercise that decided by the transplant physician; patients able to understand training instructions and follow the study protocol

You may not qualify if:

  • fever
  • smokers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zizi Mohammed Ibrahim Ali

Giza, Nnjkjk, 2136, Egypt

Location

Study Officials

  • INTSAR S WAKED, PHD

    Cairo University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Fifty patients scheduled for HSCT at the bone marrow transplant will randomly be assigned into two groups; one will receive Chest Physical Therapy in addition to routine medical treatment and the control group will receive routine medical treatment only. Outcomes will be a pulmonary function that will be measured by spirometry and respiratory muscle strength measure by Respiratory Pressure Meter. Measurements will be before three weeks before then at the end of treatment immediately before Hematopoietic Stem Cell Transplantation and the last assessment at three weeks after hematopoietic Stem Cell Transplantation for all measured variables..
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of physical therapy, Department of Physical Therapy for Burn and Plastic Surgery, Faculty of Physical Therapy, Cairo University, Egypt.

Study Record Dates

First Submitted

October 9, 2021

First Posted

November 3, 2021

Study Start

January 10, 2021

Primary Completion

August 12, 2021

Study Completion

September 20, 2021

Last Updated

November 3, 2021

Record last verified: 2021-10

Locations